“A Year of Intense Lobbying Efforts by US MNCs Failed to Sway Indian Government on Stent Pricing”: AiMed

All India Medical Devices Manufacturers’ Association (AiMed) complimented the Government for staying on course on stent pricing and not giving in to the intense lobbying by the US MNCs.

“We are happy with NPPA’s new decision to continue with their directive on price cap by not falling to the massive lobbying of overseas multi-national manufacturers. Single category on DES is scientific and continuation of the above stand gives confidence to the manufacturers”, Mr. Rajiv Nath, Forum Coordinator, AiMed said. The manufacturers could have welcomed higher pricing to accommodate inflation but guess that may be forthcoming in April review, Mr. Nath added assuring full support and cooperation from Indian manufacturers to the government, consumers and medical professionals.

A year after slashing the coronary stent price by as much as 85 percent, the National Pharmaceutical Pricing Authority (NPPA) has further reduced DES stent prices, albeit, marginally. According to the notification issued by the pricing authority, drug-eluting stents will be priced at Rs 27,890 and bare-metal stents at Rs 7,660, excluding the goods and services tax (GST), effective from 13 February 2018.

At the same time, NPPA also decided against multinational stent makers’ request for a new category for advanced stents in absence of …

To read more subscribe
Show More

Related Articles

Leave a Reply